Neuropatías adquiridas (I). Neuropatías inmunomediadas: características clínicas y valor de los autoanticuerpos

Simons, 1997, Functional rafts in cell membranes, Nature, 387, 569, 10.1038/42408 Ilyas, 1985, Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups, Ann Neurol, 18, 655, 10.1002/ana.410180605 Quarles, 1999, Autoantibodies associated with peripheral neuropathy, Muscle Nerve, 22, 800, 10.1002/(SICI)1097-4598(199907)22:7<800::AID-MUS2>3.0.CO;2-F Rojas-García, 2001, [Anti-GQ1b antibodies: usefulness of its detection for the diagnosis of Miller-Fisher syndrome], Med Clin (Barc), 116, 761, 10.1016/S0025-7753(01)71980-X Roberts, 1993, Serum factor in Miller-Fisher variant of Guillain Barré syndrome and neurotransmitter release, Lancet, 343, 454, 10.1016/S0140-6736(94)92694-8 Willison, 1999, Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies, Eur J Neurol, 6, 71, 10.1046/j.1468-1331.1999.610071.x Willison, 1994, Acute ataxic neuropathy with cross-reactive antibodies to GD1b and GD3 gangliosides, Neurology, 44, 2395, 10.1212/WNL.44.12.2395 Jacobs, 1998, The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study, Neurology, 51, 1110, 10.1212/WNL.51.4.1110 Berciano, 2000, Perineurium contributes to axonal damage in acute inflammatory demyelinating polyneuropathy, Neurology, 55, 552, 10.1212/WNL.55.4.552 Gallardo, 2001, [Antiganglioside antibodies: when, which and for what], Neurologia, 16, 293 Ang, 1999, Rapidly progressive, predominantly motor Guillain-Barre syndrome with anti-GalNAc-GD1a antibodies, Neurology, 53, 2122, 10.1212/WNL.53.9.2122 Yuki, 2000, Clinical features and response to treatment in Guillain-Barre syndrome associated with antibodies to GM1b ganglioside, Ann Neurol, 47, 314, 10.1002/1531-8249(200003)47:3<314::AID-ANA6>3.0.CO;2-C Chiba, 1992, Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome, Ann Neurol, 31, 677, 10.1002/ana.410310619 Chiba, 1997, Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome, Brain Research, 745, 32, 10.1016/S0006-8993(96)01123-7 Wicklein, 1997, Prominent sensory ataxia in Guillain-Barre syndrome associated with IgG anti-GD1b antibody, J Neurol Sci, 151, 227, 10.1016/S0022-510X(97)00136-6 Serrano-Munuera, 2001, Antiganglioside antibodies in acute self-limiting ataxic neuropathy: incidence and significance, J Neuroimmunol, 120, 78, 10.1016/S0165-5728(01)00428-3 Serrano-Munuera, 2002, Antidisialosyl antibodies in chronic idiopathic ataxic neuropathy, J Neurol, 249, 525, 10.1007/s00415-002-0882-2 Pestronk, 1988, A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside, Ann Neurol, 24, 73, 10.1002/ana.410240113 Santoro, 1990, IgM deposits at nodes of Ranvier in a patient with amyotrophic lateral sclerosis, anti-GM1 antibodies, and multifocal motor conduction block, Ann Neurol, 28, 373, 10.1002/ana.410280312 Santoro, 1992, Experimental conduction block induced by serum from a patient with anti-GM1 antibodies, Ann Neurol, 31, 385, 10.1002/ana.410310407 Kusunoki, 1996, Experimental sensory neuropathy induced by sensitization with ganglioside GD1b, Ann Neurol, 39, 424, 10.1002/ana.410390404 Yuki, 2001, Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside, Ann Neurol, 49, 712, 10.1002/ana.1012 Illa, 1995, Acute axonal Guillain-Barre syndrome with IgG antibodies against motor axons following parenteral gangliosides, Ann Neurol, 38, 218, 10.1002/ana.410380214 Willison, 1994, Human monoclonal anti-GM1 ganglioside antibodies interfere with neuromuscular transmission, Ann Neurol, 36, 289 Paparounas, 1999, Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro [see comments], Brain, 122, 807, 10.1093/brain/122.5.807 Buchwald, 1995, Immunoglobulin G from a patient with Miller-Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice, Neurosci Lett, 201, 163, 10.1016/0304-3940(95)12155-2 Ortiz, 2001, IgM monoclonal antibody against terminal moiety of GM2, GalNAc-GD1a and GalNAc-GM1b from a pure motor chronic demyelinating polyneuropathy patient: effects on neurotransmitter release, J Neuroimmunol, 119, 114, 10.1016/S0165-5728(01)00373-3 Connolly, 1997, Serum IgM monoclonal autoantibody binding to the 301 to 314 amino acid epitope of beta-tubulin: clinical association with slowly progressive demyelinating polyneuropathy, Neurology, 48, 243, 10.1212/WNL.48.1.243 Briani, 1998, Antibodies to chondroitin sulfate C: a new detection assay and correlations with neurological diseases, J Neuroimmunol, 84, 117, 10.1016/S0165-5728(97)00209-9 Pestronk, 1998, Serum antibodies to heparan sulfate glycosaminoglycans in Guillain- Barre syndrome and other demyelinating polyneuropathies, J Neuroimmunol, 91, 204, 10.1016/S0165-5728(98)00182-9 Carpo, 2000, Anti-sulfatide IgM antibodies in peripheral neuropathy, J Neurol Sci, 176, 144, 10.1016/S0022-510X(00)00342-7 Gabriel, 2000, Anti-PMP22 antibodies in patients with inflammatory neuropathy, J Neuroimmunol, 104, 139, 10.1016/S0165-5728(99)00269-6